Evaluating mainstreaming in pediatric immunology: an optimal model of care

This study demonstrates that implementing a mainstream model of care for pediatric inborn errors of immunity significantly improved genomic testing outcomes, including reduced duplicate testing and variants of uncertain significance, increased informed consent documentation, and a higher diagnostic yield.

The Gist

Imagine the human immune system as a highly sophisticated security team protecting a castle (the body). Sometimes, due to a typo in the castle's blueprints (our DNA), the security team is built with a flaw. This makes the castle vulnerable to invaders (infections), causes the guards to turn on the castle itself (autoimmunity), or leads to other chaos. These flaws are called Inborn Errors of Immunity (IEI).

For a long time, finding these specific typos was like trying to find a single missing brick in a massive wall by looking at the wall one brick at a time. It was slow, expensive, and often led to confusion.

This paper is about a team of doctors in Queensland, Australia, who decided to fix the way they search for these "typos." They built a new, smarter system called a "Mainstream Model of Care." Think of this as upgrading from a flashlight to a high-tech drone that can scan the whole wall instantly and tell you exactly where the problem is.

Here is the story of their journey, broken down simply:

1. The Problem: The "Wild West" of Testing

Before 2021, the doctors were like detectives working without a central case file.

• Confusion: Different doctors (gastroenterologists, immunologists, geneticists) were ordering different tests. Sometimes, they ordered the same test twice for the same kid because they didn't know the other doctor had already done it. This was like buying two maps of the same city when you only needed one.
• Missed Clues: Because the process was messy, they sometimes missed the real diagnosis or got stuck with "Uncertain Results" (like a map that says "Maybe there's a bridge here, maybe not").
• Delays: Kids were waiting too long to get the right treatment, sometimes getting sicker while they waited.

2. The Solution: The "Genomic Command Center"

In 2021, the team built a Model of Care (MoC). Imagine this as setting up a Command Center with a clear set of rules and a special team.

• The Monthly Huddle: Once a month, all the experts (doctors, geneticists, pathologists) sit around a table to review every case together. It's like a "war room" where they share notes so no one works in a silo.
• The Embedded Guide: They hired a Genetic Counselor to sit right inside the immunology clinic. Think of this person as a "tour guide" who helps families understand the complex DNA maps before they even start the test.
• The Best Tool: They started using a "Trio-Exome" test. Instead of just looking at the child's DNA, they look at the child's DNA plus the parents' DNA. It's like looking at a child's photo alongside their parents' photos to instantly spot which feature was inherited and which one is the "typo."

3. The Results: Smarter, Faster, Better

After putting this new system in place, the results were like night and day:

• No More Duplicate Tests: The "duplicate testing" (buying two maps) dropped from 14% to 0%. They stopped wasting money and time.
• Fewer "Maybe" Answers: The number of confusing "Uncertain Results" dropped from 38% to just 7%. The team got clearer answers.
• More "Yes" Answers: The rate of actually finding the diagnosis (the "Diagnostic Yield") went up from 16% to 27%. They were finding the missing bricks more often.
• Better Paperwork: The doctors got much better at getting permission (consent) from parents before testing, ensuring families were fully informed.

4. Why It Matters: Saving Lives and Changing Lives

Finding the diagnosis isn't just about a label; it's about the action plan.

• The Right Key for the Lock: Once they know the exact genetic flaw, they can choose the right medicine. For some kids, this means a bone marrow transplant (a total security team replacement). For others, it means a specific pill that stops the immune system from overreacting.
• Avoiding Mistakes: Knowing the diagnosis prevents doctors from giving the wrong treatment that could actually hurt the child (like using radiation on a child whose DNA makes them sensitive to it).
• Family Peace of Mind: It helps parents understand why their child is sick and allows them to check if other family members (like siblings) might be at risk.

The Bottom Line

This paper shows that when you organize a chaotic system into a coordinated team effort, you get better results for the patients.

Before, the doctors were running around with flashlights in the dark, bumping into each other. Now, they have a drone, a map, and a command center. They are finding the problems faster, wasting less money, and, most importantly, giving children the right treatment sooner so they can grow up healthy.

The authors conclude that this "Mainstream Model" should be the standard way of doing things everywhere, not just in Queensland. It turns a confusing, stressful journey for families into a clear, guided path to healing.

Technical Summary

1. Problem Statement

Inborn Errors of Immunity (IEI) are a heterogeneous group of genetic disorders affecting the immune system, often presenting in childhood with severe, life-limiting complications. While genomic testing is critical for establishing a molecular diagnosis to guide targeted therapies (e.g., hematopoietic stem cell transplantation, gene therapy) and reproductive counseling, the integration of genomics into routine immunology care remains suboptimal.

• Gaps Identified: There is a lack of standardized Models of Care (MoC) for patient identification, consent, test selection, and result communication.
• Consequences: The absence of a dedicated MoC leads to healthcare inefficiencies, including missed diagnostic opportunities, delays in curative treatment, duplicate testing, and poor management of Variants of Uncertain Significance (VUS).
• Context: Prior to this study, there was limited data on Australian pediatric IEI cohorts and no evidence describing the impact of a structured genomic MoC on service delivery.

2. Methodology

• Study Design: A comprehensive retrospective chart audit and observational study conducted at the Queensland Paediatric Immunology and Allergy Service (QPIAS), a tertiary pediatric hospital in Australia.
• Cohort: 322 patients (≤18 years) who underwent IEI genomic testing between 2017 and 2025.
• Data Collection:
  • Data was extracted from clinical charts, pathology portals, and internal files.
  • Variables included demographics, testing indications, modality (e.g., panel, exome, trio), results, and management outcomes.
  • Socio-demographic data was mapped against Australian Statistical Geography Standard (ASGS) and SEIFA indices.
• Intervention (The Model of Care): The study evaluated the impact of implementing a specific genomic MoC at QPIAS, which included:
  • Monthly multidisciplinary team (MDT) meetings for case review.
  • An embedded genetic counselor.
  • A dedicated clinical immunologist specializing in genomics.
  • Adoption of trio-exome sequencing via virtual panel analysis as a front-line test.
  • Collaboration with statewide pathology services.
• Analysis Strategy:
  • Temporal Comparison: Outcomes were compared between the pre-MoC period (<2021) and the post-MoC period (≥2021).
  • Statistical Methods: Descriptive statistics and Chi-square tests were used to assess changes in diagnostic yield, duplicate testing rates, VUS rates, and consent documentation (significance set at p < 0.05).

3. Key Contributions

• First Australian Pediatric IEI Cohort: Provides the first detailed characterization of a pediatric IEI cohort and genomic testing practices within the Australian healthcare system.
• Evidence for Mainstreaming: Demonstrates that integrating genomics into mainstream immunology care via a structured MoC significantly improves service efficiency and clinical outcomes.
• Operational Framework: Offers a replicable framework (Box 1 in the paper) for implementing genomic MoCs, emphasizing MDT collaboration, trio-testing, and dynamic eligibility criteria.
• Diagnostic Yield Insights: Highlights specific clinical phenotypes (e.g., VEO-IBD) where initial broad testing criteria yielded low results, prompting a refinement of testing eligibility.

4. Key Results

• Cohort Characteristics:
  • 322 patients (mean age at first test: 5.9 years); 53.7% male.
  • Most common indications: Very Early Onset Inflammatory Bowel Disease (VEO-IBD, 21.1%), immune dysregulation (11.8%), and atypical infections (9.9%).
• Testing Practices:
  • Total of 481 genomic tests ordered (1.5 tests/patient).
  • Duplicate Testing: Pre-MoC, 13.9% of tests were duplicates; post-MoC, this dropped to 0%.
  • Trio Testing: Utilization of trio-analysis (proband + parents) increased significantly from 18.1% (pre-MoC) to 66.7% (post-MoC).
• Diagnostic Yield:
  • Overall Yield: 27.6% (89/322 patients).
  • Yield by Indication: Highest in Phagocytic defects (100%) and SCID (80%); lowest in VEO-IBD (4.4%).
  • Temporal Improvement: Diagnostic yield increased significantly from 16.2% (pre-MoC) to 27.4% (post-MoC) (p < 0.05).
• Quality Metrics:
  • VUS Rate: Decreased significantly from 37.7% (pre-MoC) to 7.1% (post-MoC).
  • Consent Documentation: Improved from 70.5% to 88.4%.
  • Pathology Integration: Post-MoC, 87% of tests were conducted via the state pathology service (Pathology Queensland) compared to 16.6% pre-MoC.
• Clinical Impact:
  • Management Changes: 90.5% of patients with a molecular diagnosis received a change in management (e.g., HSCT, immunoglobulin replacement, targeted therapies like JAK inhibitors).
  • Mortality: 60% of deceased patients (6/10) received a molecular diagnosis, often guiding post-mortem understanding or family cascade testing.

5. Significance and Implications

• Clinical Efficiency: The study proves that a structured MoC eliminates redundant testing and improves the diagnostic yield, directly translating to cost savings and faster time-to-treatment.
• Therapeutic Precision: High rates of management changes underscore the necessity of early molecular diagnosis to initiate life-saving interventions (e.g., avoiding toxic conditioning regimens in specific SCID subtypes).
• Policy and Funding: The authors highlight a critical gap in Australian healthcare: the lack of a specific Medicare Item Number for IEI genomic testing. They argue that funding schemes alone are insufficient without implementation strategies (workforce, education, MoC).
• Future Directions: The study advocates for:
  • Regular re-analysis of genomic data (every 2–3 years) to capture new gene discoveries.
  • Adaptive eligibility criteria (e.g., restricting VEO-IBD testing to infants <2 years unless specific features are present).
  • Strengthening collaboration between immunologists, geneticists, and pathologists to resolve VUS and improve variant classification.

Conclusion: The implementation of a targeted genomic Model of Care in pediatric immunology is a viable and necessary strategy to optimize the delivery of genomic testing, reduce healthcare waste, and significantly improve patient outcomes through timely, precision medicine.